Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Functional and Clinical Characterization of the Putative Tumor Suppressor WWOX in Non-small Cell Lung Cancer

Functional and Clinical Characterization of the Putative Tumor Suppressor WWOX in Non-small Cell... ORIGINAL ARTICLE Functional and Clinical Characterization of the Putative Tumor Suppressor WWOX in Non-small Cell Lung Cancer Silvan Becker, MD,* Boyka Markova, PhD,* Rainer Wiewrodt, MD,‡ Sandra Hoffarth,* Patricia S. Ha¨hnel, PhD,* Sina Pleiner, MSc,* Lars Hennig Schmidt, MD,‡ Frank Breitenbuecher, PhD,* and Martin Schuler, MD*† on-small cell lung cancers (NSCLCs) are the leading Introduction: The oxidoreductase WWOX was initially described Ncause of cancer mortality in the Western World. Al- as a putative tumor suppressor in breast cancer. Non-small cell lung though inhalative cigarette smoking has been established as cancers (NSCLCs) frequently show aberrant WWOX expression. the dominant risk factor for the development of NSCLC, the Herein, we characterized WWOX at a functional level in preclinical complete oncogenic process is less well characterized and NSCLC models and in primary NSCLC biopsies. certainly differs between various histologically and geneti- Methods: The human wild-type (wt) WWOX complementary DNA cally defined NSCLC subsets. Recently, the concept of “ge- A132T and a mutant WWOX with structurally disrupted short-chain netic dependence” to specific oncogenic “driver mutations” dehydrogenase/reductase domain were conditionally expressed at has drawn much attention in lung cancer pathophysiology physiological levels in several human NSCLC models. Resulting research. It has been paradigmatically demonstrated http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Functional and Clinical Characterization of the Putative Tumor Suppressor WWOX in Non-small Cell Lung Cancer

Schuler, Martin
Journal of Thoracic Oncology , Volume 6 (12) – Dec 1, 2011
Download PDF
8 pages

Loading next page...
 
/lp/wolters-kluwer-health/functional-and-clinical-characterization-of-the-putative-tumor-JUhcxq7A2s

References (30)

ISSN
1556-0864
DOI
10.1097/JTO.0b013e31822e59dd
pmid
21892104
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE Functional and Clinical Characterization of the Putative Tumor Suppressor WWOX in Non-small Cell Lung Cancer Silvan Becker, MD,* Boyka Markova, PhD,* Rainer Wiewrodt, MD,‡ Sandra Hoffarth,* Patricia S. Ha¨hnel, PhD,* Sina Pleiner, MSc,* Lars Hennig Schmidt, MD,‡ Frank Breitenbuecher, PhD,* and Martin Schuler, MD*† on-small cell lung cancers (NSCLCs) are the leading Introduction: The oxidoreductase WWOX was initially described Ncause of cancer mortality in the Western World. Al- as a putative tumor suppressor in breast cancer. Non-small cell lung though inhalative cigarette smoking has been established as cancers (NSCLCs) frequently show aberrant WWOX expression. the dominant risk factor for the development of NSCLC, the Herein, we characterized WWOX at a functional level in preclinical complete oncogenic process is less well characterized and NSCLC models and in primary NSCLC biopsies. certainly differs between various histologically and geneti- Methods: The human wild-type (wt) WWOX complementary DNA cally defined NSCLC subsets. Recently, the concept of “ge- A132T and a mutant WWOX with structurally disrupted short-chain netic dependence” to specific oncogenic “driver mutations” dehydrogenase/reductase domain were conditionally expressed at has drawn much attention in lung cancer pathophysiology physiological levels in several human NSCLC models. Resulting research. It has been paradigmatically demonstrated

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Dec 1, 2011

There are no references for this article.